Idasanutlin

Overview

Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC 50 of 6 nM. Idasanutlin disrupts MDM2 - p53 binding, stabilizes and activates p53 , triggering cell cycle arrest, apoptosis , and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2 , MEK1/2 , ERK1/2 , AKT , mTOR , p70(S6K1) , and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3 -dependent apoptosis and gasdermin E-mediated pyroptosis . Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer , T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Blood Disease | Products > Disease Areas > Melanoma | Products > Disease Areas > Neuroblastoma | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Osteosarcoma | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Acute Myeloid Leukemia | Products > Disease Areas > Non-Hodgkin Lymphoma | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > NF-κB | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > E1/E2/E3 Enzyme | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Pyroptosis

Product Information

• Catalog No.: HY-15676
• CAS No.: 1229705-06-9
• Molecular Formula: C31H29Cl2F2N3O4
• Molecular Weight: 616.48
• Purity: 99.93%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (4.06 mM); Clear solution
• Availability: In-stock

Source

Original product source